| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | ROR 1, NTRKR1, Neurotrophic tyrosine kinase, OTTMUSP00000008344, Receptor tyrosine kinase like orphan receptor 1, Neurotrophic tyrosine kinase receptor related 1, RP11 24J23.1, Inactive tyrosine-protein kinase transmembrane receptor ROR1, Tyrosine protein kinase transmembrane receptor ROR1, ROR1_HUMAN, Tyrosine-protein kinase transmembrane receptor ROR1, Tyrosine kinase like orphan receptor 1, OTTHUMP00000010574, ROR1, RGD1559469, Neurotrophic tyrosine kinase, receptor related 1, receptor-related 1, dJ537F10.1, OTTHUMP00000010573, MGC99659 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Gene ID | |
| Host | |
| Immunogen | Synthetic peptide from the mid-protein of Human ROR1 (aa. 200-300) |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a member of the ROR family of transmembrane proteins involved in non-canonical Wnt signaling. While ROR1 is best known for its role in embryonic development and cancer biology, emerging evidence highlights its significance in the nervous system, particularly in the context of neurodegenerative diseases.
In the adult brain, ROR1 expression is typically low but becomes upregulated in response to injury or pathological stress. Recent studies have shown that ROR1 can counteract cytoskeletal degradation induced by amyloid-beta (Aβ1–42), a hallmark of Alzheimer’s disease. Overexpression of ROR1 in neuronal models preserves actin filament integrity, promotes neuritogenesis, and mitigates Aβ-induced cytoskeletal instability.
ROR1 is also regulated by non-coding RNAs, including miR-146a and NEAT1, which are dysregulated in Alzheimer’s disease. This regulatory axis suggests that ROR1 is part of a broader epigenetic network influencing neuronal structure and resilience. Additionally, ROR1-mediated signaling may support axonal growth, synaptic maintenance, and neuroregeneration through Wnt5a-dependent pathways.
Given its role in maintaining cytoskeletal architecture and responding to neurotoxic stress, ROR1 represents a promising therapeutic target for neurodegenerative diseases. Modulating ROR1 expression or activity could offer novel strategies to preserve neuronal integrity and slow disease progression.
Cite this product varies by variant:
- SPC-762D — Size: 100 ug: ROR1 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-762D, RRID: AB_2728980)
- SPC-762D-A390 — Size: 100 ug: ROR1 Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-762D-A390, RRID: AB_2731347)
- SPC-762D-A488 — Size: 100 ug: ROR1 Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-762D-A488, RRID: AB_2731348)
- SPC-762D-A594 — Size: 100 ug: ROR1 Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-762D-A594, RRID: AB_2731350)
- SPC-762D-APC — Size: 100 ug: ROR1 Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-762D-APC, RRID: AB_2731356)
- SPC-762D-BI — Size: 100 ug: ROR1 Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-762D-BI, RRID: AB_2731357)
- SPC-762D-FITC — Size: 100 ug: ROR1 Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-762D-FITC, RRID: AB_2731358)
- SPC-762D-HRP — Size: 100 ug: ROR1 Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-762D-HRP, RRID: AB_2731359)
- SPC-762D-PCP — Size: 100 ug: ROR1 Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-762D-PCP, RRID: AB_2731361)
- SPC-762D-RPE — Size: 100 ug: ROR1 Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-762D-RPE, RRID: AB_2731362)
- SPC-762S — Size: 12 ug: ROR1 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-762S, RRID: AB_2728980)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Makin, S. (2025, April 16). The future of Alzheimer’s treatment. Nature Outlook: Alzheimer’s Disease. https://www.nature.com/articles/d41586-025-01102-2